Clinical Trial Update: Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) [Phase 3]

View source ↗

Summary

Phase 3 HUDSON GI study evaluating benralizumab for eosinophilic gastritis and eosinophilic gastroenteritis was terminated. Results addressing efficacy and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Gastritis
• Eosinophilic Gastroenteritis

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Status: TERMINATED | Results posted: 2025-07-14